Top section
Top section
◆ Have capital markets comprehended the heatwave? ◆ Which SSA issuers need to get it done this autumn ◆ Halcyon days for MTN, M&A and ECM bankers
Investors pay little heed to alarming worsening of climate
New $75m partnership to develop treatment for lymphoma was “catalyst for investors”
More articles
More articles
More articles
-
South Korean company SK Biopharmaceuticals is planning to launch an IPO by the end of 2019 and could net proceeds of up to around W1tr ($838.5m), according to a source close to the deal. -
Marel, the Icelandic meat processing machinery maker, has announced its intention to seek an additional listing on Euronext Amsterdam before the summer, as it aims to tap into growing global demand for meat products.
-
JP Morgan has raised €400m by issuing a cash-settled bond, exchangeable into shares of Siemens, at an extremely aggressive price level. The purpose of the deal is not clear.
-
Tikehau Capital, the French alternative investment manager, has raised €300m after a private capital raising led by Morgan Stanley.
-
Hansoh Pharmaceutical Group has won approval from the Hong Kong Stock Exchange for a new listing worth up to $1bn.
-
Biopharmaceutical company Mabpharm has launched the deal roadshow for its IPO and is targeting proceeds of up to HK$1.53bn ($194.7m).
Sub-sections
shared comment list
